Prem Senthil Mallika, Khadka Jyoti, Pesudovs Konrad
NHMRC Centre for Clinical Eye Research, Flinders University of South Australia, Adelaide, South Australia, Australia.
NHMRC Centre for Clinical Eye Research, Flinders University of South Australia, Adelaide, South Australia, Australia.
Surv Ophthalmol. 2017 Jul-Aug;62(4):546-582. doi: 10.1016/j.survophthal.2016.12.011. Epub 2017 Jan 3.
Advances in the understanding of the genetic, molecular, and cellular biology of retinal diseases have led to the development of new treatments. These expanding treatment options demand appropriate outcome measures for studies of treatment benefit including patient-reported outcomes (PROs). A plethora of PRO instruments assess impacts of retinal diseases from the patients' perspectives. We review all the studies that implemented PRO assessment in retinal diseases and also discuss quality assessment of the PRO instruments. We also include qualitative studies that explored quality of life impact on people with retinal diseases. Most studies used PRO instruments not specifically developed for retinal diseases (non-disease specific), nor have they undergone comprehensive validation in this disease group. A few retina-specific PRO instruments are available, but they suffer from limited content coverage of quality of life. Finally, we discuss the need for a new comprehensive and technologically advanced PRO instrument to assess quality of life impacts in retinal diseases.
对视网膜疾病的遗传、分子和细胞生物学理解的进展已促成了新治疗方法的开发。这些不断增加的治疗选择要求有适当的疗效指标来研究治疗益处,包括患者报告结局(PROs)。大量的PRO工具从患者角度评估视网膜疾病的影响。我们回顾了所有在视网膜疾病中实施PRO评估的研究,并讨论了PRO工具的质量评估。我们还纳入了探索视网膜疾病患者生活质量影响的定性研究。大多数研究使用的PRO工具并非专门为视网膜疾病开发(非疾病特异性),也未在该疾病组中进行全面验证。有一些视网膜特异性PRO工具,但它们在生活质量的内容覆盖方面有限。最后,我们讨论了需要一种新的全面且技术先进的PRO工具来评估视网膜疾病对生活质量的影响。